Diamond Biofund Past Earnings Performance
Past criteria checks 0/6
Diamond Biofund's earnings have been declining at an average annual rate of -56%, while the Capital Markets industry saw earnings growing at 13.3% annually. Revenues have been declining at an average rate of 56.1% per year.
Key information
-56.0%
Earnings growth rate
-57.1%
EPS growth rate
| Capital Markets Industry Growth | 12.7% |
| Revenue growth rate | -56.1% |
| Return on equity | -14.0% |
| Net Margin | 111.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Diamond Biofund makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | -1,407 | -1,561 | 161 | 0 |
| 30 Jun 24 | -1,905 | -2,060 | 154 | 0 |
| 31 Mar 24 | -3,220 | -3,364 | 153 | 0 |
| 31 Dec 23 | -2,440 | -2,583 | 148 | 0 |
| 30 Sep 23 | -3,684 | -3,831 | 112 | 0 |
| 30 Jun 23 | -1,104 | -1,244 | 102 | 0 |
| 31 Mar 23 | -1,943 | -2,076 | 70 | 0 |
| 31 Dec 22 | 1,016 | 798 | 102 | 0 |
| 30 Sep 22 | 3,563 | 3,343 | 128 | 0 |
| 30 Jun 22 | 3,756 | 3,555 | 91 | 0 |
| 31 Mar 22 | 6,015 | 5,762 | 112 | 0 |
| 31 Dec 21 | 3,064 | 2,852 | 64 | 0 |
| 31 Dec 20 | 6,501 | 6,090 | 404 | 0 |
| 31 Dec 19 | -303 | -371 | 64 | 0 |
Quality Earnings: 6901 is currently unprofitable.
Growing Profit Margin: 6901 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6901 is unprofitable, and losses have increased over the past 5 years at a rate of 56% per year.
Accelerating Growth: Unable to compare 6901's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6901 is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (18%).
Return on Equity
High ROE: 6901 has a negative Return on Equity (-14.03%), as it is currently unprofitable.